Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 18, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 510,000 ordinary shares of 25 pence each.
- Purchase Price: 1,470.4709 pence per share.
- Treasury Holdings: 193,626,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,792,527,170 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 17, 2006. The company executed the purchase on September 18, 2006, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the 510,000 share repurchase based on the disclosed price of 1,470.4709 pence.
- Confirm the updated total share count and Treasury holdings against subsequent filings.
- Review the May 17, 2006 Annual General Meeting minutes to understand the full scope of the share buyback authorization.